New hope for Hard-to-Treat lung condition: satralizumab trial targets inflammation
NCT ID NCT05679570
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This Phase 2 trial tests whether satralizumab, an antibody that blocks IL-6 (a protein involved in inflammation), can improve blood flow in the lungs of people with pulmonary arterial hypertension (PAH). The study includes 20 adults in Japan who have high IL-6 levels and haven't responded well to standard treatments. Participants receive satralizumab injections every few weeks, and researchers measure changes in lung blood vessel resistance and walking distance after 24 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Satralizumab (an anti-IL-6 receptor antibody)
What this could lead to
If successful, this could provide a new treatment option for people with pulmonary arterial hypertension who have high IL-6 levels and don't respond well to existing drugs.
What could go wrong
This is a small, early-stage Phase 2 trial with only 20 participants in Japan. It may not show enough benefit or could have side effects, and results may not apply to all PAH patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chiba University Hospital
Chiba, 260-8677, Japan
-
Hokkaido University Hospital
Sapporo, 060-8648, Japan
-
International University of Health and Welfare Mita Hospital
Tokyo, 108-8329, Japan
-
Kagoshima University Hospital
Kagoshima, Kagoshima-ken, 890-8520, Japan
-
Kobe University Hospital
Kobe, 650-0017, Japan
-
Kurume University Hospital
Kurume, 830-0011, Japan
-
Kyorin University Hospital
Mitaka, 181-8611, Japan
-
Kyushu University Hospital
Fukuoka, 812-8582, Japan
-
Nagoya University Hospital
Nagoya, 466-8560, Japan